Merck & Company (MRK) Stock Price, Quote & News

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health manageme...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 908 740 4000

Website: www.merck.com

Address:

126 East Lincoln Avenue, Rahway, United States

Mike22332233 Jul. 1 at 11:03 PM

$SLS UPDATED ... I said the following one month ago when SLS was $8-$9 about it going to $18-$22 after 80th event ... and people laughed ... I don't hear from them anymore !!! ... Timeline/Price Prediction: ... SLS will jump to $18-$22 after 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results 2 weeks later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a possible 5 way Bidding War -- between $MRK, $ABBV, $BMY, $PFE, and RHHBY -- the FINAL BO PRICE will be reached at $202 in Q4 of 2026 !!! ... LIKE & FOLLOW me 👉 @Mike22332233 for SLS insight you will find nowhere else

1 · Reply

Fingerlickengood Jul. 1 at 10:24 PM

$CDXS $MRK The shorts continue to exit this scene! https://fintel.io/ss/us/cdxs

0 · Reply

StocktwitsNews Jul. 1 at 10:01 PM

MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership $MRK $VTI $VOO $NEUP https://stocktwits.com/news/equity/markets/mrk-neup-stocks-drop-as-merck-scraps-another-alzheimers-drug-under-neuphoria-partnership/cZm3ANLR711

0 · Reply

AStrokeOfLuck Jul. 1 at 6:54 PM

$MRK $NEUP

0 · Reply

Mike22332233 Jul. 1 at 6:35 PM

$SLS DID YOU SEE MY STUNNING PREDICTION ... If the REGAL GPS trial comes in with my estimated HR of 0.27-0.33 (or lower), which would be AMAZINGLY GAME CHANGING ... We will get BO bids (and a bidding war) FROM EACH OF THE FOLLOWING: $MRK $BMY $PFE $ABBV RHHBY That's correct ... ALL 5 OF THEM!!! ... Like if you agree & FOLLOW ME @Mike22332233 for BO price

1 · Reply

StockRadarr Jul. 1 at 6:21 PM

$MRK has terminated a Phase 2 trial for its experimental Alzheimer's drug (MK-1167), an asset partnered with Neuphoria. The decision follows a prespecified interim analysis showing the drug failed to meet efficacy criteria.

0 · Reply

JackCampbell Jul. 1 at 4:54 PM

$CTXR $CTOR for all crying about Lenny here...its really irrelevant. Relevant is that Lymphir is the one and only approved T-reg depleting therapy on the market, delivering unmatched efficacy in its class. By breaking down immune resistance, it serves as a powerful cornerstone for next-generation oncological combination therapies.$MRK $GILD and many other....

3 · Reply

10D_west Jul. 1 at 3:50 PM

$MRK We're so close to fresh ATHs I can smell it probably hit them by the end of the month.

0 · Reply

MoneyFairyBlessings Jul. 1 at 3:09 PM

$MRK $145 coming up.

0 · Reply

CoffeeRocks Jul. 1 at 2:40 PM

$CODX possibly Dilution solution $MRK

0 · Reply

Merck terminates Phase 2 Alzheimer’s study

Jul 1, 2026, 6:45 AM EDT - 13 hours ago

Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4

2026-06-30T14:15:11.000Z - 1 day ago

Merck price target raised to $155 from $136 at Scotiabank

2026-06-30T14:05:22.000Z - 1 day ago

House committee opens probe into Merck, AbbVie China drug trials, Reuters says

ABBV

2026-06-30T12:05:18.000Z - 1 day ago

Merck price target raised to $141 from $130 at BofA

Jun 30, 2026, 6:02 AM EDT - 1 day ago

US House committee opens investigation into Merck, AbbVie China drug trials

ABBV

Jun 29, 2026, 5:08 PM EDT - 2 days ago

Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?

2026-06-29T18:35:14.000Z - 2 days ago

Merck price target raised to $155 from $136 at Scotiabank

Jun 29, 2026, 6:45 AM EDT - 2 days ago

Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV

Jun 25, 2026, 1:00 PM EDT - 6 days ago

The Big 3: JPM, DHR, MRK

DHR JPM

2026-06-25T10:50:37.000Z - 6 days ago

Merck says FDA approves Keytruda and Keytruda Qlex in combo with Trodelvy

GILD

Jun 25, 2026, 6:45 AM EDT - 6 days ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)

2026-06-24T10:50:33.000Z - 7 days ago

Merck says EC approves Keytruda plus Padcev combination

Jun 24, 2026, 6:45 AM EDT - 7 days ago

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

2026-06-24T01:00:13.000Z - 7 days ago

Merck initiated with an Outperform at CICC

Jun 23, 2026, 10:00 AM EDT - 8 days ago

Merck and Mae Partner to Expand Doula Workforce and Address Maternal Health Disparities in High-Risk U.S. Markets

Jun 22, 2026, 7:16 AM EDT - 9 days ago

Merck's bowel disease drug meets main goal in late-stage trial

2026-06-22T10:47:10.000Z - 9 days ago

Merck announces ‘positive’ results from Phase 3 trial of tulisokibart

Jun 22, 2026, 6:45 AM EDT - 9 days ago

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

2026-06-18T10:50:55.000Z - 13 days ago

Merck says FDA approves additional indication for Capvaxive

Jun 18, 2026, 6:45 AM EDT - 13 days ago

Merck's pneumococcal vaccine wins US approval for high-risk children, teens

Jun 18, 2026, 6:45 AM EDT - 13 days ago

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease

Jun 17, 2026, 6:45 AM EDT - 14 days ago

Study Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All Ages

Jun 16, 2026, 8:00 AM EDT - 15 days ago

Protillion Biosciences Announces Drug Discovery Collaboration with Merck

Jun 12, 2026, 4:10 PM EDT - 19 days ago

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)

Jun 11, 2026, 7:14 AM EDT - 20 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ABBV ALKS AMGN GILD IBB IHE JNJ

Jun 11, 2026, 6:45 AM EDT - 20 days ago

Merck Animal Health to Acquire TARGAN

Jun 9, 2026, 11:20 AM EDT - 22 days ago

Merck & Co. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 22 days ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN JNJ LLY NVO PFE

Jun 9, 2026, 3:20 AM EDT - 22 days ago

The space race is coming for pharma: Why drug development is heading to lower Earth orbit

BMY LLY PFE RDW UTHR XBI

Jun 8, 2026, 4:35 PM EDT - 23 days ago

Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment

GILD

Jun 8, 2026, 4:30 PM EDT - 23 days ago

Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study

GILD

Jun 8, 2026, 8:00 AM EDT - 23 days ago

Rejuvenate Bio Announces $6 Million Financing and Strategic R&D Collaboration with Merck Animal Health

Jun 4, 2026, 10:30 AM EDT - 27 days ago

Merck & Co. Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 6:45 AM EDT - 4 weeks ago

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 1, 2026, 7:00 PM EDT - 4 weeks ago

Merck & Co. Transcript: Investor update

Jun 1, 2026, 7:00 PM EDT - 4 weeks ago

Merck & Co. Press release: Investor update

Jun 1, 2026, 7:00 PM EDT - 4 weeks ago

Merck & Co. Slides: Investor update

Jun 1, 2026, 12:55 PM EDT - 4 weeks ago

Merck exec says company is discussing use of COVID antiviral drug in Ebola response

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

MRNA

May 29, 2026, 6:45 AM EDT - 4 weeks ago

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

May 28, 2026, 6:45 AM EDT - 4 weeks ago

Merck to Participate in the Jefferies Global Healthcare Conference

May 27, 2026, 2:23 PM EDT - 5 weeks ago

Merck and Mastercard are seeing real agentic AI results. Both say the plumbing came first.

May 27, 2026, 3:10 AM EDT - 5 weeks ago

Merck chicken bronchitis vaccine approved for use in China

May 26, 2026, 1:28 PM EDT - 5 weeks ago

Merck Announces Third-Quarter 2026 Dividend

May 26, 2026, 9:00 AM EDT - 5 weeks ago

Merck & Co. Transcript: AGM 2026

May 26, 2026, 9:00 AM EDT - 5 weeks ago

Merck & Co. Slides: FY 2026

May 22, 2026, 2:31 PM EDT - 5 weeks ago

Merck stock jumps as Keytruda combo trials boost cancer pipeline

May 22, 2026, 10:23 AM EDT - 5 weeks ago

Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

May 22, 2026, 7:55 AM EDT - 5 weeks ago

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer

May 21, 2026, 5:06 PM EDT - 5 weeks ago

Kelun, Merck's lung cancer combo improves survival in late-stage China trial

May 21, 2026, 5:03 PM EDT - 5 weeks ago

Moderna, Merck cancer combo cuts melanoma spread risk at five years

MRNA

May 21, 2026, 8:00 AM EDT - 5 weeks ago

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer

May 20, 2026, 11:00 AM EDT - 6 weeks ago

National Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing Claims

May 18, 2026, 6:51 AM EDT - 6 weeks ago

Merck's endometrial cancer drug meets late-stage trial goals

May 18, 2026, 6:45 AM EDT - 6 weeks ago

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer

May 12, 2026, 6:45 AM EDT - 7 weeks ago

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

May 7, 2026, 2:05 PM EDT - 7 weeks ago

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

May 6, 2026, 9:00 AM EDT - 2 months ago

Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees

CRM

May 5, 2026, 8:45 AM EDT - 2 months ago

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

TERN

May 4, 2026, 4:56 PM EDT - 2 months ago

Merck (MRK) Price Forecast: Double Top Signals Deeper Correction Risk

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Merck & Co. Earnings Call Transcript: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Merck & Co. Earnings release: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Merck & Co. Slides: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Merck & Co. Quarterly report: Q1 2026

Apr 30, 2026, 8:05 AM EDT - 2 months ago

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations

Apr 30, 2026, 6:51 AM EDT - 2 months ago

Merck Sales Rise on Continued Keytruda Growth

Apr 30, 2026, 6:32 AM EDT - 2 months ago

Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook

Apr 30, 2026, 6:31 AM EDT - 2 months ago

Merck posts quarterly loss due to Cidara charge, sales rise 5%

Apr 30, 2026, 6:30 AM EDT - 2 months ago

Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones

Apr 28, 2026, 6:45 AM EDT - 2 months ago

Merck's Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke

Mike22332233 Jul. 1 at 11:03 PM

1 · Reply

Fingerlickengood Jul. 1 at 10:24 PM

$CDXS $MRK The shorts continue to exit this scene! https://fintel.io/ss/us/cdxs

0 · Reply

StocktwitsNews Jul. 1 at 10:01 PM

0 · Reply

AStrokeOfLuck Jul. 1 at 6:54 PM

$MRK $NEUP

0 · Reply

Mike22332233 Jul. 1 at 6:35 PM

1 · Reply

StockRadarr Jul. 1 at 6:21 PM

0 · Reply

JackCampbell Jul. 1 at 4:54 PM

3 · Reply

10D_west Jul. 1 at 3:50 PM

$MRK We're so close to fresh ATHs I can smell it probably hit them by the end of the month.

0 · Reply

MoneyFairyBlessings Jul. 1 at 3:09 PM

$MRK $145 coming up.

0 · Reply

CoffeeRocks Jul. 1 at 2:40 PM

$CODX possibly Dilution solution $MRK

0 · Reply

PittsburghTrader Jul. 1 at 1:52 PM

$MRK hmm, time to buy this pullback?

0 · Reply

Trader_Ty Jul. 1 at 1:26 PM

$MRK A few bucks lower and trade is there

0 · Reply

Xen_TorpedoCapital Jul. 1 at 12:57 PM

$MRVL $MU $SNDK Given $MRK is doing fine so far, technically markets are still BULLISH. It's just the weakness in the chips as predicted by $SOXL

0 · Reply

GordoHLYK13 Jul. 1 at 12:10 PM

$IGC Millions of families are watching dementia stories hit the national spotlight. Every headline shines a brighter light on the urgent need for better Alzheimer’s treatments—and that’s exactly where IGC Pharma is making its move. With Phase 2 CALMA topline results expected soon, IGC has a major catalyst on the horizon. Positive data could put this micro-cap squarely on Big Pharma’s radar while bringing hope to patients and caregivers worldwide. The dementia race is just heating up. 🧠🚀 Tags: $IGC $LLY $BIIB $MRK $PFE

0 · Reply

Xen_TorpedoCapital Jul. 1 at 8:48 AM

$MRK $KKR $TM

0 · Reply

TheStockTraderHub Jul. 1 at 2:09 AM

Been digging through the GEX board and one thing stands out on $MRK The market keeps coming back to $135. Need to get back above 132 first, but that's clearly the level options traders have circled. 👀

0 · Reply

DidYouReadThis Jun. 30 at 11:33 PM

$OTLK Pausing emotions and hype, what’s your most #realistic #potential #buyout target after 7/29/26 potential FDA Approval for $OTLK’s wet AMD potential blockbuster opthalmic bevacizumab? $PFE $MRK $REGN

2 · Reply

taxplanr Jun. 30 at 9:59 PM

$BNTX $MRNA $PFE $MRK all still treating cancer wrong https://www.instagram.com/reel/DZX9tifTEM0/?igsh=MTlka3V5dDl4Y3VncA==

0 · Reply

TalkMarkets Jun. 30 at 8:53 PM

Innovation Drives Gains In #Biotech Stocks $ARKG $IBB $LLY $MRK $XBI https://talkmarkets.com/article/innovation-drives-gains-in-biotech-stocks-1782852729

0 · Reply

Buy_SoFi Jun. 30 at 8:37 PM

$TLTFF <--- MAJOR NEWS!!! 💥 $100 million in financing now accessible! $IBRX $CGON $ENGN $MRK

0 · Reply

Magnificient Jun. 30 at 7:36 PM

$IOVA no mercy but $MRK

0 · Reply

AStrokeOfLuck Jun. 30 at 6:43 PM

$PFE $MRK

0 · Reply

Market Cap	319.55B
Revenue (ttm)	65.01B
Net Income (ttm)	18.25B
EPS (ttm)	N/A
PE Ratio	23.52
Forward PE	24.89
Profit Margin	28.08%
Debt to Equity Ratio	1.02

Volume	10,761,238
Avg Vol	10,588,702
Day's Range	N/A - N/A
Shares Out	2.47B
Stochastic %K	90%
Beta	0.21
Analysts	Strong Sell
Price Target	$131.74